Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA dermatology

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamadermatol.2016.5668PMID 28329382PMCID PMC5817620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of systemic steroids in the outcome of Stevens-Johnson syndrome and toxic epidermal

  2016cited by this paper
• Intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis: a meta‐analysis with meta‐regression of observational studies

  2015cited by this paper
• Severe drug‐induced skin reactions: clinical features, diagnosis, etiology, and therapy

  2015cited by this paper
• Epidermal necrolysis: 60 years of errors and advances

  2015cited by this paper
• Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.

  2015cited by this paper
• Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.

  2014cited by this paper
• Severe cutaneous adverse reactions in a local hospital setting: a 5‐year retrospective study

  2014cited by this paper
• Retrospective Analysis of Corticosteroid Treatment in Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis over a Period of 10 Years in Vajira Hospital, Navamindradhiraj University, Bangkok

  2014cited by this paper
• Beneficial therapeutic effects of hemoperfusion in the treatment of severe Stevens-Johnson syndrome/toxic epidermal necrolysis: preliminary results.

  2014cited by this paper
• Etanercept therapy for toxic epidermal necrolysis.

  2014cited by this paper
• Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm.

  2014cited by this paper
• Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.

  2014cited by this paper
• Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers.

  2013cited by this paper
• Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

  2013cited by this paper
• Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid.

  2013cited by this paper
• French referral center management of Stevens–Johnson syndrome/toxic epidermal necrolysis

  2013cited by this paper
• Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department – Cagliari University (Italy)

  2012influential reference
• Toxic epidermal necrolysis: five years of treatment experience from a burn unit.

  2012cited by this paper
• Toxic Epidermal Necrolysis: Performance of SCORTEN and the Score-Based Comparison of the Efficacy of Corticosteroid Therapy and Intravenous Immunoglobulin Combined Therapy in China

  2012cited by this paper
• Causative Drugs and Clinical Outcome in Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS-TEN Overlap in Children

  2012influential reference
• Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.

  2012cited by this paper
• The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta‐analysis

  2012cited by this paper
• Síndrome de Stevens-Johnson

  2011cited by this paper
• Hematological abnormalities and the use of granulocyte‐colony‐stimulating factor in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis

  2011cited by this paper
• Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.

  2011influential reference
• Systematic review of treatments for Stevens–Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality

  2011cited by this paper
• Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children

  2011influential reference
• Stevens-Johnson syndrome in Thai children: a 29-year study.

  2011cited by this paper
• Serum Bicarbonate as a Marker to Predict Mortality in Toxic Epidermal Necrolysis

  2011cited by this paper
• Stevens‐Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a University Hospital

  2011influential reference
• What Are the Fluid Requirements in Toxic Epidermal Necrolysis?

  2010cited by this paper
• Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis

  2010cited by this paper
• Aquacel Ag with Vaseline gauze in the management of toxic epidermal necrolysis (TEN).

  2010influential reference
• Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children.

  2010cited by this paper
• Does hypernatremia impact mortality in Toxic Epidermal Necrolysis?

  2010cited by this paper
• Toxic epidermal necrolysis successfully treated with etanercept

  2009cited by this paper
• Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond

  2009cited by this paper
• Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens–Johnson syndrome: a retrospective comparative study in China

  2009cited by this paper
• Life-Threatening Dermatoses and Emergencies in Dermatology

  2009cited by this paper
• Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes

  2009cited by this paper
• Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.

  2009influential reference
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

  2008cited by this paper
• Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis

  2008cited by this paper
• SCORTEN Accurately Predicts Mortality Among Toxic Epidermal Necrolysis Patients Treated in a Burn Center

  2008cited by this paper
• A 12-year retrospective study of non-burn skin loss (burn-like syndromes) at a tertiary burns unit in a developing country.

  2008cited by this paper
• Oral manifestations of toxic epidermal necrolysis (TEN) in patients with AIDS: report of five cases.

  2008cited by this paper
• Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.

  2008influential reference
• Antishear Therapy for Toxic Epidermal Necrolysis: An Alternative Treatment Approach

  2008influential reference
• TOXIC EPIDERMAL NECROLYSIS/STEVENS–JOHNSON SYNDROME: CURRENT TRENDS IN MANAGEMENT

  2007cited by this paper
• Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre.

  2007influential reference
• A clinical experience of treating exfoliative wounds using nanocrystalline silver-containing dressings (Acticoat).

  2007cited by this paper
• [Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome].

  2007influential reference
• Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.

  2007cited by this paper
• Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.

  2007influential reference
• Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome.

  2007influential reference
• [Lyell's syndrome: a report of 16 cases].

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

  2007cited by this paper
• Severe bullous skin diseases: analysis of seven children managed in a burns unit.

  2006cited by this paper
• Management of Dysphagia in Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS)

  2006cited by this paper
• [Toxic epidermic necrolysis].

  2006cited by this paper
• SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol

  2006cited by this paper
• Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis

  2006cited by this paper
• Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis.

  2006cited by this paper
• Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment

  2005cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Syndrome de Stevens-Johnson et nécrolyse épidermique toxique à Lomé (Togo)

  2005cited by this paper
• Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center.

  2005cited by this paper
• Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.

  2005cited by this paper
• Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients.

  2005influential reference
• Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment.

  2005cited by this paper
• [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].

  2005cited by this paper
• High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits

  2005influential reference
• Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis.

  2004cited by this paper
• Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis

  2004cited by this paper
• Toxic epidermal necrolysis: does immunoglobulin make a difference?

  2004cited by this paper
• Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States.

  2004cited by this paper
• Human herpesvirus infection in drug-induced hypersensitivity syndrome, toxic epidermal necrolysis and Stevens-Johnson syndrome

  2004influential reference
• Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.

  2003cited by this paper
• Therapie mit Glukokortikoiden: Risiken und Nebenwirkungen

  2003cited by this paper
• Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.

  2003cited by this paper
• Antitumour necrosis factor‐α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis

  2002cited by this paper
• Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children

  2002influential reference
• Interventions for toxic epidermal necrolysis.

  2002cited by this paper
• Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children.

  2002influential reference
• Outcome of Patients with Toxic Epidermal Necrolysis Syndrome Revisited

  2002cited by this paper
• A 10-year experience with toxic epidermal necrolysis.

  2001cited by this paper
• Treatment of extensive toxic epidermal necrolysis in children.

  2001cited by this paper
• Treatment of toxic epidermal necrolysis with cyclosporin A.

  2000influential reference
• Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

  2000cited by this paper
• A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies.

  2000cited by this paper
• Toxic epidermal necrolysis in Western Australia

  2000cited by this paper
• Methods for Meta-Analysis in Medical Research

  2000cited by this paper
• Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome

  2000influential reference
• Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?

  1999cited by this paper
• Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.

  1998influential reference
• Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia

  1998influential reference
• Toxic Epidermal Necrolysis Syndrome: Mortality Rate Reduced with Early Referral to Regional Burn Center

  1998cited by this paper
• Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study

  1997cited by this paper
• Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage.

  1997cited by this paper
• Toxic epidermal necrolysis in a burns centre: a 6-year review.

  1996cited by this paper

• Adverse Drug Reaction to Paracetamol: Case Report of Oral Manifestation of Stevens-Johnson Syndrome in Children.

  2026cites this paper
• Systemische immunmodulierende Therapien der epidermalen Nekrolyse (Stevens‐Johnson‐Syndrom/toxisch epidermale Nekrolyse): Systematische Übersicht und Metaanalyse

  2026cites this paper
• Case Report: A case of toxic epidermal necrolysis induced by serplulimab: integrated Chinese and Western nursing care.

  2026cites this paper
• Biologic Therapies For Dermatologic Emergencies: A Comprehensive Review.

  2025cites this paper
• Drug-Induced Toxic Epidermal Necrolysis: A Case Report

  2025cites this paper
• Systemic immunomodulating therapies for epidermal necrolysis (Stevens‐Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta‐analysis

  2025influential citation
• Evaluation of clinical features and treatment modality of pediatric patients with Steven Johnson syndrome/toxic epidermal necrolysis: a single-center experience

  2025cites this paper
• Síndrome de Stevens-Johnson por alopurinol en una mujer portadora del alelo HLA-B*58:01

  2025cites this paper
• Stevens-Johnson Syndrome with a 24-Hour Onset Following a Single Dose of Ibuprofen: A Case Report and Review

  2025cites this paper
• Hypersensitivity Reactions to Anticonvulsants

  2025cites this paper
• Outcome measures in Stevens–Johnson syndrome/toxic epidermal necrolysis: a systematic review

  2025cites this paper
• Toxic epidermal necrolysis: lessons from three fatal cases.

  2025cites this paper
• Clinical features of Stevens — Johnson syndrome and toxic epidermal necrolysis: An observational cohort retrospective study

  2025cites this paper
• Mucosal-Dominant Stevens-Johnson Syndrome Presenting as Hemorrhagic Glossitis in a Multimorbid Patient: A Diagnostic Challenge

  2025cites this paper
• Progressive Immunotherapy-Related Mucocutaneous Eruption: A Mimicker of SJS-TEN.

  2025cites this paper
• Drug-induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Ten-year Retrospective Study of 103 Cases.

  2025cites this paper
• Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Current Management and Innovative Therapies

  2025cites this paper
• Incidence of the Stevens‐Johnson syndrome spectrum and its patterns in urban China

  2025cites this paper
• Severe Cutaneous Adverse Reaction to Lamotrigine: A Case of Stevens-Johnson Syndrome in a Psychiatric Patient

  2025cites this paper
• Intensivpflichtige Hauterkrankungen

  2025cites this paper
• Abordaje en urgencias del Síndrome de Stevens-Johnson y la Necrólisis Epidérmica Tóxica: actualización, manejo integral y perspectivas terapéuticas

  2025cites this paper
• Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023.

  2025cites this paper
• Recent advances in the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.

  2025cites this paper
• The Potential Roles of IL-1β, IL-6, and RIPK3 in the Pathogenesis of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis

  2025cites this paper
• Risk factors for Stevens — Johnson syndrome and toxic epidermal necrolysis

  2025cites this paper
• An Atypical Case of Toxic Epidermal Necrolysis Associated With Ceftriaxone

  2025cites this paper
• Síndrome de Steven Jhonson / Necrólisis epidérmica tóxica: revisión de literatura y actualización

  2025cites this paper
• Unravelling Stevens-Johnson Syndrome: Clinicopathological Insights and Therapeutic Advances.

  2025cites this paper
• A case of toxic epidermal necrolysis in a paediatric patient with mycoplasma pneumoniae infection

  2025cites this paper
• Inhibition of formyl peptide receptor-1-mediated cell death as a therapy for lethal cutaneous drug reactions in preclinical models

  2025cites this paper
• Adult Reactive Infectious Mucocutaneous Eruption (RIME) from Concurrent Adenovirus and Mycoplasma pneumoniae Infections

  2025cites this paper
• Update in Diagnosis and Management of Severe Cutaneous Adverse Reactions: Emerging Therapies and Evolving Presentations

  2025cites this paper
• Allopurinol‐Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Case Reports and Case Series

  2025cites this paper
• Consider systemic therapy alongside supportive care in the early phases of Stevens–Johnson syndrome/toxic epidermal necrolysis

  2025cites this paper
• Stevens Johnson Syndrome/Toxic Epidermal Necrolysis – Diagnostic Testing and Treatment for Ophthalmologists

  2025cites this paper
• Intensivpflichtige Hauterkrankungen

  2025cites this paper
• The case for etanercept in the management of toxic epidermal necrolysis

  2025cites this paper
• Cilostazol or canagliflozin mitigates Cyclosporine A-induced nephrotoxicity by modulating the STAMP2-mTOR-AMPK signaling pathway and autophagy in a rat model.

  2025cites this paper
• Toxic epidermal necrolysis – clinicopathological aspects and therapeutic management

  2024cites this paper
• Agminated Eruptive Melanocytic Nevi and Nail Changes Following Toxic Epidermal Necrolysis in a Pediatric Patient: A Case Report and Systematic Review of the Literature

  2024cites this paper
• Severe Cutaneous Adverse Reactions: A Narrative Literature Review

  2024cites this paper
• Cyclophilin A: promising target in cancer therapy

  2024cites this paper
• Cutaneous adverse drug reactions in children with a focus on hypersensitivity to systemic drugs: A narrative review

  2024cites this paper
• Case Report: Multi-targeted therapy in the treatment of severe toxic epidermal necrolysis

  2024cites this paper
• Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients

  2024cites this paper
• Effectiveness of early treatment with plasma exchange in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis

  2024cites this paper
• Idiopathic toxic epidermal necrolysis in a pediatric patient

  2024cites this paper
• Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments

  2024cites this paper
• S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy

  2024cites this paper
• Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy

  2024cites this paper
• Oral Cyclosporine Treatment for Four Pediatric Patients With Toxic Epidermal Necrolysis That Showed No Response to High-dose Corticosteroids in Combination With Intravenous Immunoglobulin: A Case Series

  2024influential citation
• Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Cohort Study of 216 Patients in an Inpatient Dermatology Department

  2024cites this paper
• Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management

  2024cites this paper
• Advancements in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Treatment: Utilizing Fas-Fas Ligand Inhibition to Target Cell Death Signaling Pathways for Practical Human Application.

  2024cites this paper
• S3‐Leitlinie: Diagnostik und Therapie der epidermalen Nekrolyse (Stevens‐Johnson‐Syndrom und toxisch epidermale Nekrolyse) – Teil 1: Diagnostik, initiales Management und immunmodulierende Systemtherapie

  2024cites this paper
• Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review

  2024cites this paper
• Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review

  2024cites this paper
• Clinical Features of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor versus Non-Immune Checkpoint Inhibitor Drugs in China: A Cross-Sectional Study and Literature Review

  2024cites this paper
• Stevens–Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report

  2024cites this paper
• Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.

  2024cites this paper
• Improvement of the Ocular Prognosis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A National Survey in Japan.

  2024cites this paper
• Severe cutaneous adverse reactions

  2024cites this paper
• Afatinib‐induced toxic epidermal necrolysis: A case report with a literature review

  2024cites this paper
• High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis.

  2024cites this paper
• Effect of Early Cyclosporine Treatment on Survival in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  2024cites this paper
• Modulation of cyclophosphamide-induced immunosuppression and intestinal flora in broiler by deep eutectic solvent extracted polysaccharides of Acanthopanax senticosus

  2024cites this paper
• D-Penicillamine-Induced Stevens–Johnson Syndrome in a Patient with Gold Cyanide Intoxication: A Case Report

  2024cites this paper
• Toxic epidermal necrolysis caused by viral hepatitis A: a case report and literature review

  2024cites this paper
• Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids

  2023cites this paper
• Nécrolyse épidermique (syndromes de Stevens-Johnson et de Lyell) : manifestations cliniques et prise en charge

  2023cites this paper
• Phenytoin-Induced Toxic Epidermal Necrolysis

  2023cites this paper
• Toxic Epidermal Necrolysis, A Serious Side Effect of Tenoxicam Use: A Case Report

  2023cites this paper
• Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

  2023cites this paper
• Penicillamine-Induced Stevensjohnson Syndrome-Toxic Epidermal Necrolysis (Sjs-Ten) Overlap In An Hiv-Infected Patient With Wilson's Disease And Hepatitis B.

  2023cites this paper
• Schwere kutane Arzneimittelreaktionen bei Kindern

  2023cites this paper
• Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome

  2023cites this paper
• Ophthalmic Aspects of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review

  2023cites this paper
• New insights into the diagnosis and management of Stevens–Johnson syndrome and toxic epidermal necrolysis

  2023cites this paper
• Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

  2023cites this paper
• Genitourinary Management and Follow-Up for Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

  2023cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

  2023cites this paper
• Cyclosporine monotherapy in pediatric Stevens–Johnson syndrome and toxic epidermal necrolysis: Preserving sepsis indicators while promoting recovery

  2023cites this paper
• Immune checkpoint inhibitor‐induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications

  2023cites this paper
• Toxic epidermal necrolysis after injection of sclerosing agent and medical adhesive into oesophageal variceal ligation in a patient with a malignant liver tumour: A case report

  2023cites this paper
• Stevens-Johnson syndrome and toxic epidermal necrolysis - 11-year retrospective experience in a high complexity tertiary hospital in Milan, Italy.

  2023cites this paper
• Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.

  2023cites this paper
• A retrospective analysis of mortality risk and immunosuppressive therapy for Stevens-Johnson Syndrome and toxic epidermal necrolysis syndrome using the TriNetX research network.

  2023cites this paper
• Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Fresh Look at an Old Foe

  2023cites this paper
• Role of Silver Nitrate Spray for Skin Wound Care in Patients with Toxic Epidermal Necrolysis: Our Experience in 4 Patients

  2023cites this paper
• Allopurinol-Induced Stevens–Johnson Syndrome (SJS)

  2023cites this paper
• Advances in the Pathomechanisms of Delayed Drug Hypersensitivity.

  2022cites this paper
• CCID_A_356450 547..556

  2022influential citation
• Clinical aspects and therapeutic approach of drug-induced adverse skin reactions in a quaternary hospital: a retrospective study with 219 cases

  2022cites this paper
• The Correlation of Neutrophil–Lymphocyte Ratio and Eosinophil Count with SCORTEN in SJS/TEN

  2022influential citation
• Immunomodulatory treatment of Lyell's syndrome - a simultaneous plasmapheresis and IVIGs therapy.

  2022cites this paper
• Amoxicillin-associated Stevens-Johnson syndrome or toxic epidermal necrolysis: systematic review

  2022cites this paper
• Letter from the Editor: The use and misuse of systematic reviews and meta-analysis.

  2022cites this paper
• The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study

  2022cites this paper
• Use of Cyclosporine Therapy in Dermatology During COVID-19 Pandemic

  2022cites this paper
• Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies

  2022cites this paper